ResearcherAzienda USL di BolognaNo recent work listed
Michela Visani
Matched on ORCID iD 0000-0002-9051-2231; OpenAlex author ID A5057019569. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper
Papers 4
- Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. First author DOI 10.1007/s11033-020-05763-2↗
- Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.pan.2017.11.001↗
- Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Co-author DOI 10.3233/cbm-170464↗
- Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells. Co-author DOI 10.1177/1066896912475073↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Carlo Fabbri · 4 shared papers, 2013–2020 · strength 0.25
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Paper Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. DOI 10.1016/j.pan.2017.11.001↗
- Dario de Biase · 4 shared papers, 2013–2020 · strength 0.25
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Paper Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. DOI 10.1016/j.pan.2017.11.001↗
- Sirio Fiorino · 3 shared papers, 2018–2020 · strength 0.21
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Paper Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. DOI 10.1016/j.pan.2017.11.001↗
- Elio Jovine · 3 shared papers, 2018–2020 · strength 0.21
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Paper Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. DOI 10.1016/j.pan.2017.11.001↗
- Michele Masetti · 3 shared papers, 2018–2020 · strength 0.21
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Paper Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. DOI 10.1016/j.pan.2017.11.001↗
- Giovanni Tallini · 3 shared papers, 2013–2020 · strength 0.19
- Paper Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. DOI 10.1007/s11033-020-05763-2↗
- Paper Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. DOI 10.3233/cbm-170464↗
- Paper Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of… DOI 10.1177/1066896912475073↗
- Chiara Birtolo · 1 shared paper, 2018 · strength 0.05
- Nicola Zanini · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.